EUROPE-HIGH-GROWTH-FUND
12.2.2024 22:16:25 CET | Business Wire | Press release
European High Growth Opportunities Securitization Fund (the “Fund”), acting through and represented by European High Growth Opportunities Manco SA, each of which is an investment vehicle advised by Alpha Blue Ocean, responds to a press release dated February 1, 2024 issued by Tony G Co-Investment Holdings Ltd. (the “Company”), pursuant to which the Company asserted that it is not bound by its obligations under the terms of the $1,288,000 principal amount convertible debenture of the Company dated August 10, 2021 (the “Debenture”) and purported to issue shares to the Fund.
The Fund would like to notify shareholders of the Company that the Fund rejects the purported share issuance and continues to allege that the Company is bound by, and in breach of, its obligations under the Debenture. The Fund continues to pursue its claim against the Company which will be heard by the Ontario Superior Court of Justice (the “Court”) on November 22, 2024. The Fund reminds both management and the board of directors of the Company that they are bound by their fiduciary obligations to the Company and all stakeholders.
In addition, given the actions of the Company, its management and its board of directors, including Messrs. Antanas Guoga and Ron Akram, the Fund is currently exploring all other avenues of recourse available, including relief under the oppression remedy and relief available from the Canadian Securities Exchange (the “CSE”) and the Ontario Securities Commission with respect to this matter.
In the Fund’s opinion, the Company has failed to provide clear guidance to the market regarding its obligations under the Debenture and the claim that was commenced by the Fund or to comply with its obligations to issue press releases with respect to material changes. The Fund’s position is that:
- As a result of the occurrence of several events of default under the Debenture and the underlying subscription agreement (including the Company’s failure to issue securities to the Fund in a timely manner and the Company’s securities being suspended from trading on the CSE on June 6, 2022), the Fund exercised its rights under the Debenture on November 21, 2022 and demanded the Company immediately pay the sum of $1,288,000 in cash pursuant to the terms of the Debenture;
- Although the monies owed by the Company to the Fund accrue interest at a rate of 40% per annum, compounded monthly, the Company has flouted its obligation to repay the Fund for more than a year, focusing instead on the completion of a series of related party transactions that the Fund believes erode the value of stakeholders for the benefit of insiders;
- On December 7, 2022, the Fund was forced to initiate a proceeding in the Court for, among other things, the payment of $1,288,000, plus interest at the rate of 40% per annum, compounded monthly; and
- In November 2023, the Fund agreed to engage in settlement discussions with the Company and, as an illustration of the Fund’s good faith efforts to resolve the dispute, agreed to extend certain Court deadlines only to have the Company suddenly terminate settlement discussions through the unilateral purported issuance of shares to the Fund and accompanying press release on February 1, 2024, which the Fund believes misrepresents the Company’s liability.
The Fund denies the validity of the share issuance to the Fund and will continue to seek recourse against the Company through its litigation in the Court.
The Fund regrets needing to bring legal proceedings against the Company in order for the Company to comply with its obligations under the Debenture and wishes to put an expeditious end to these distractions.
About European High Growth Opportunities Securitization Fund
European High Growth Opportunities Securitization Fund is a fund based in Luxembourg which is in the business of investing in high growth companies.
Forward-looking statements
This press release contains forward-looking statements. All statements contained in this press release that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” “intends,” and similar expressions are generally intended to identify forward-looking statements. These statements are based on current expectations of the Fund and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Fund’s ability to control or predict, that may cause the actual results to differ materially from those discussed in the forward-looking statements. Forward-looking statements in this press release include, among other things, statements regarding the intentions of the Fund with respect to the Debenture and the litigation (including any potential settlement thereof and the Company’s conduct in connection therewith). Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, that the litigation will be resolved in a manner that is unfavourable to the Company and that the Company will be required to pay amounts or issue shares to the Fund in defending, resolving, or in connection with, the litigation. The forward-looking statements included in this press release are made as of the date of this press release and the Fund does not assume any obligation to update any forward-looking statements contained in this press release, except as required by applicable law.
Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this press release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212603262/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
